Background: Recent Children's Oncology Group (COG) trials tested the efficacy of reduced therapy in an effort to lessen late effects compared to the Intergroup Rhabdomyosarcoma Study (IRS) IV regimen with associated hematologic and hepatic toxicity, and infertility. Here, we analyze the efficacy of 45 Gray (Gy) local radiotherapy (RT) in patients with Group III orbital embryonal rhabdomyosarcoma (ERMS) enrolled on the COG low-risk study ARST0331.
INTRODUCTION
Approximately 10% of rhabdomyosarcomas (RMS) arise in the orbit. 1 Orbital RMS rarely presents with regional or metastatic disease.
Because of the morbidity associated with complete resection, orbital RMS is usually Group III and radiotherapy (RT) has typically been used for local control. Using this approach, the 5-year failure-free survival (FFS) rate for patients with Group III orbital embryonal RMS (ERMS) exceeds 85%, with a lower FFS rate for patients with nonembryonal histology. [2] [3] [4] [5] [6] [7] [8] In Intergroup Rhabdomyosarcoma Study (IRS) III, patients with Group III orbital RMS were treated with 41.4-50.4 Gray (Gy) depending on age using conventional fractionation with vincristine (VCR) and dactinomycin (DACT; VA). The 5-year local failure rate was 16%. 4 In IRS-IV, patients with Group III orbital RMS were randomized to receive either 50.4 Gy in 28 daily fractions or 59.4 Gy in twice daily hyperfractionated dosing starting after 9 weeks of chemotherapy, and they were also randomized to receive either VA plus 26.4 g/m 2 of cyclophosphamide (CPM; VCR, DACT, and CPM [VAC]), VA plus ifosfamide, or VCR plus ifosfamide and etoposide. The 5-year local failure rate was 2% and 3-year FFS was 94%. Local control rates were not different between conventional fractionation and hyperfractionation. 5, 6 The two most recent clinical trials conducted by the Children's Oncology Group (COG) Soft Tissue Sarcoma Committee have tested reduced-intensity chemotherapy and RT regimens for orbital ERMS.
In COG D9602, patients with Group III orbital ERMS received 45 Gy in conventional fractionation after 3 weeks of chemotherapy and VA over 45 weeks. The 5-year local failure rate was 14%. 7, 8 Given superior IRS-IV FFS and local control rates with chemotherapy regimens that included an alkylating agent, the primary objective of COG ARST0331 was to reduce the length of therapy without compromising FFS by using VA in combination with lower dose CPM (total cumulative dose, 4.8 g/m 2 ) plus RT for patients with subset 1 low-risk ERMS, which included those with Group III orbital ERMS. 9, 10 As with COG D9602, patients with Group III orbital ERMS received 45 Gy in conventional fractionation on COG ARST0331. The 3-year FFS and overall survival (OS) for eligible patients with primary orbital tumors were 87% and 97%, respectively. The overall study objective for subset 1 low-risk patients was met. 11 We assessed whether initial response to chemotherapy predicted outcome for patients with unresected orbital ERMS on ARST0331 and report here local recurrence rate, FFS, and OS.
PROCEDURES

Patients
Eighty-two eligible patients with ERMS of the orbit or eyelid were treated on ARST0331. Of those patients, 62 had orbital Group III disease, all of whom had orbital primary disease. The eligibility requirements for this study have been previously published. 11 
Treatment
Patients with Stage 1, Group III orbital RMS were assigned to subset 1 of ARST0331 and received four cycles of VAC followed by four cycles of VA over 22 weeks and RT starting after 12 weeks of chemotherapy.
DACT was omitted during RT. Chemotherapy dosing was based on age. Radiation oncology plans were centrally reviewed by the Quality Assurance Review Center. Study RT guidelines permitted deviations from study guidelines for patients aged ≤24 months.
Statistical analysis
Records were reviewed for response following four cycles of VAC chemotherapy over 12 weeks, local recurrences, FFS, and OS. ; the other three did not progress but went off protocol therapy before week 13 for reasons of "physician determination," "refusal by patient/parent," and "Intolerable toxicity."
time from the start of treatment to death from any cause. The KaplanMeier method was used to estimate FFS and OS distributions. 12 Confidence intervals (CIs) were calculated using Greenwood's formula. 13 Recurrence was defined as local if the tumor recurred at the site of primary disease, regional if regional lymph nodes were involved, and distant if metastatic disease was present at the time of recurrence.
Only first recurrences were considered for this analysis. Differences between curves were analyzed by the log-rank test. Data regarding infertility or ocular late effects were not collected on ARST0331. Analyses were based on data available by July 2016. 
RESULTS
Patient characteristics and outcomes
Response to 12 weeks of VAC chemotherapy and associated outcomes
Fifteen patients (24%) had a CR to VAC chemotherapy and 38 patients (61%) had <CR either a PR (n = 31) or SD (n = 7). Two patients (4%) had PD before week 12 evaluation, and seven patients (11%) had insufficient or missing week 12 evaluation data.
There were eight events, all of which were local disease progression either before RT (n = 2) or following RT (n = 6). There were six local failures among the 31 patients with PR. There were no events among the patients with CR or SD following induction chemotherapy. Six of the eight patients are alive following local recurrence. The salvage regimens were not collected by the study. The two patients died of PD, including the infant in the study who did not receive RT. There was no difference in 5-year OS between patients with CR (100%) and PR/SD (97%; 95% CI, 91-100%) at week 12 (P = 0.52).
Protocol RT deviations did not differ between patients with recurrence (one minor deviation among six patients) and patients without recurrence (10 minor deviations among 47 patients). Eight deviations (including one in a patient with a recurrence) were related to CTV or PTV delineation, and three deviations were related to target volume coverage. There were no deviations for total radiation dose. 
TA B L E 2 Treatment and outcome for Group III orbital ERMS
DISCUSSION
As shown in Table 2 , among IRS Group (IRSG) and COG studies preceding ARST0331, the highest local control rate for patients with Group Gy of RT. The eye preservation rate was 86% but impaired visual acuity occurred in 70% of the remaining patients. 17 The marginal increase in toxicity between 45 and 50.4 Gy is unknown, and none of the most recent trials collected data regarding ocular function. With modern radiation techniques including three-dimensional conformal, intensity modulated, volumetric modulated arc, and proton RT, treatments have become increasingly more conformal, thus decreasing the likelihood of similar ocular findings. 18, 19 The overall prognosis remained favorable for patients with Group III orbital ERMS on ARST0331. Indeed, for patients with Group III orbital ERMS with a CR at week 12 to neoadjuvant chemotherapy on ARST0331, there were no local recurrences using 45 Gy, suggesting this combination of chemotherapy and RT may be adequate for these patients. Trials assessing further reduction in RT are unlikely for this rare subset of patients.
However, a higher local failure rate among patients on ARST0331
with <CR suggests that these patients may benefit from alternative approaches. Local control, FFS, OS acute toxicity, and long-term morbidity should be taken into account to determine the optimal treatment approach for patients with Group III orbital ERMS. IRS-IV therapy had the most favorable local control and FFS rates, although with more toxicity. Dose escalation to 50.4 Gy for patients with Group III orbital ERMS on a backbone of ARST0331 chemotherapy has not been studied prospectively for efficacy, but should have an acceptable toxicity profile and was previously used for many patients on IRS-III and IRS-IV. Positron emission tomography response 20 or gene expression signatures such as MG5 21 could be investigated in the future to identify candidates for augmented or reduced therapy. Finally, one could hypothesize that earlier identification of patients with <CR could allow intensified therapy to those patients; however, doing so could subject some patients to more intensive therapy who would have achieved a CR to induction chemotherapy by week 13.
CONCLUSIONS
For patients with low-risk Group III orbital ERMS achieving a CR following induction chemotherapy on ARST0331 that includes modest dose CPM, 45 Gy may be sufficient for durable FFS. However, for patients with Group III orbital ERMS with <CR after induction chemotherapy, the ARST0331 treatment algorithm is associated with lower poorer local control than was achieved on the more intensive IRS-IV therapy and warrants consideration of different local treatment algorithms in future RMS clinical trials.
